1. MRD Analysis in Chronic Lymphocytic Leukemia

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. This Program's Key Topics

4. What Is MRD in Hematologic Malignancies?

5. Why Measure MRD in CLL?

6. When Could We Measure MRD?

7. PCR for the Detection of MRD

8. Flow Cytometry for the Detection of MRD

9. MRD Analysis in CLL Using Flow Cytometry

10. Next-Generation Sequencing

11. U-MRD Prediction of PFS Is Largely Independent of Treatment

12. MRD Level Functions as a Continuous Variable

13. U-MRD is Prognostic Independent of Clinical Response After Chemoimmunotherapy

14. Disease Biology Still Matters Even When You Know MRD Status

15. Multivariable Analysis From CLL8 and CLL10 PFS Data

16. Can We Use MRD as an Endpoint in Clinical Trials?

17. What Do We Do About Post-Treatment MRD Positivity?

18. What About Interim MRD Analysis?

19. Patients With >1% MRD After C3 FCR Have Poor Outcomes

20. MRD in the Setting of Novel Therapies

21. MURANO: Superior PFS Benefit With Fixed-Duration VenR at 3 Years

22. PB U-MRD Rates Are Higher With VenR Than BR at End of Treatment

23. U-MRD Status at End of Therapy Is Highly Predictive of Prolonged PFS

24. MRD Re-Emergence After FCR Precedes Clinical Progression

25. MRD-Directed Therapy With Venetoclax

26. MRD Monitoring Post-AlloSCT CLL3X Study

27. The Future of MRD Analysis in CLL

28. Abbreviations

29. Abbreviations (cont)